A Safety Study of SGN-LIV1A in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients
with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.